Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

18.Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021 (in thousands, except share and per share amounts):

	Year Ended December 31,
	2023			2022			2021
Net loss attributable to Adaptive Biotechnologies Corporation	$	(225,250	)	$	(200,191	)	$	(207,279	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		144,383,294			142,515,917			140,354,915
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(1.56	)	$	(1.40	)	$	(1.48	)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021, as they had an anti-dilutive effect:

	Year Ended December 31,
	2023		2022		2021
Stock options outstanding		13,839,067		13,892,287		13,097,374
Nonvested restricted stock units outstanding		9,630,579		4,799,850		693,173
Maximum nonvested market-based restricted stock units outstanding eligible to be earned		1,663,961		410,282		—
Common stock warrant outstanding		—		—		8,570
Total		25,133,607		19,102,419		13,799,117